We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Protalix BioTherapeutics Inc | AMEX:PLX | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.06 | 5.45% | 1.16 | 1.16 | 1.12 | 1.13 | 259,161 | 18:37:57 |
Prospectus Supplement No. 1 (To Prospectus Dated April 29, 2020) |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-237736 |
Common Stock
This Prospectus Supplement supplements, and should be read in conjunction with, our Prospectus included in Registration Statement on Form S-3 (Registration No. 333-237736) dated April 29, 2020 (the “Prospectus”). This Prospectus Supplement must be delivered with the Prospectus.
The information in the Prospectus in the section titled “Selling Stockholders” is amended by this Prospectus Supplement to reflect the transfer by Highbridge Tactical Credit Master Fund, L.P. of a warrant to purchase 489,938 shares of our common stock to Highbridge Tactical Credit Institutional Fund, Ltd.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this Prospectus Supplement. Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement is July 7, 2023.
SELLING STOCKHOLDERS
SUPPLEMENTAL INFORMATION
The table beginning on page 8 of the Prospectus in the section titled “Selling Stockholders” is amended as follows.
The table is hereby revised to reflect the following transfer: Highbridge Tactical Credit Master Fund, L.P. transferred warrants to purchase 489,938 shares of our common stock to Highbridge Tactical Credit Institutional Fund, Ltd. The beneficial ownership information for the selling stockholder listed below is as of July 1, 2023 and is based on 71,580,762 shares outstanding as of such date.
Shares of Common Stock Beneficially Owned Prior to the Offering | Shares of Common Stock Being Offered Hereby | Shares of Common Stock Beneficially Owned After Completion of the Offering |
||||||||||||||||||
Name of Selling Stockholder | Number | Percent | Number | Number | Percent | |||||||||||||||
Highbridge Tactical Credit Master Fund, L.P. (1)(2) | 1,923,549 | 2.7% | 1,923,549 | - | - | |||||||||||||||
Highbridge Tactical Credit Institutional Fund, Ltd. (1)(2) | 489,938 | 0.7% | 489,938 | - | - |
(1) Highbridge Capital Management, LLC, a Delaware limited liability company, serves as the investment adviser to both Highbridge Tactical Credit Master Fund, L.P. and Highbridge Tactical Credit Institutional Fund, Ltd.
(2) Does not include shares of our common stock issuable upon conversion of our outstanding 7.50% Senior Secured Convertible Promissory Notes Due September 2024 held by Highbridge Tactical Credit Master Fund, L.P.
1 Year Protalix BioTherapeutics Chart |
1 Month Protalix BioTherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions